Carolin Miklitz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Carolin Miklitz has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Klaus Fliessbach
Department of Old Age Psychiatry and Cognitive Disorders, University Hospital Bonn and University of Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-Campus 1, 53127 Bonn, Germany
3 shared publicationsAnja Schneider
Department of Old Age Psychiatry and Cognitive Disorders, University Hospital Bonn and University of Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-Campus 1, 53127 Bonn, Germany
2 shared publications- Michael Wagner
Department of Psychiatry and Psychotherapy, University Hospital Bonn, Bonn, Germany
2 shared publications Alexander Radbruch
Department of Diagnostic and Interventional Neuroradiology and Pediatric Neuroradiology University Hospital Bonn Bonn Germany
1 shared publication- Alfredo Ramirez
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
1 shared publication Alois Martin Sprinkart
Department of Diagnostic and Interventional Radiology University Hospital Bonn Bonn Germany
1 shared publication
Latest Publications
- Open Access
- 1 July 2026
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 18 (3) , e70495
Locally deployed large language model for real‐world lecanemab eligibility pre‐screening
INTRODUCTION: The introduction of disease‐modifying Alzheimer's therapies requires complex, labor‐intensive patient screening. Cloud‐based large language models (LLMs) could support this task but are often unsuitable for routine care due to data protection constraints. METHODS: We evaluated an on‐premises, open‐weights LLM (gpt‐oss‐120b) for automated extraction of therapy‐relevant variables for lecanemab eligibility from German memory clinic reports. In a two‐stage design, LLM‐based extraction prompts, a deterministic rule‐based extractor, and a shared downstream rule‐based classifier were optimized on a development set ( n = 97) and evaluated on an independent hold‐out set ( n = 99), with expert consensus as ground truth. RESULTS: The LLM‐based pipeline achieved 94% accuracy and a Cohen's kappa of 0.90 on the hold‐out set, significantly surpassing the rule‐based comparator (80% accuracy) and demonstrating performance comparable to human experts. DISCUSSION: A locally deployed, on‐premises LLM may assist eligibility screening as a triage support tool, potentially facilitating access to novel therapies without compromising patient data privacy.
- 1 July 2026
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 18 (3) , e70495
Open AccessLocally deployed large language model for real‐world lecanemab eligibility pre‐screening
INTRODUCTION: The introduction of disease‐modifying Alzheimer's therapies requires complex, labor‐intensive patient screening. Cloud‐based large language models (LLMs) could support this task but are often unsuitable for routine care due to data protection constraints. METHODS: We evaluated an on‐premises, open‐weights LLM (gpt‐oss‐120b) for automated extraction of therapy‐relevant variables for lecanemab eligibility from German memory clinic reports. In a two‐stage design, LLM‐based extraction prompts, a deterministic rule‐based extractor, and a shared downstream rule‐based classifier were optimized on a development set ( n = 97) and evaluated on an independent hold‐out set ( n = 99), with expert consensus as ground truth. RESULTS: The LLM‐based pipeline achieved 94% accuracy and a Cohen's kappa of 0.90 on the hold‐out set, significantly surpassing the rule‐based comparator (80% accuracy) and demonstrating performance comparable to human experts. DISCUSSION: A locally deployed, on‐premises LLM may assist eligibility screening as a triage support tool, potentially facilitating access to novel therapies without compromising patient data privacy.
- Open Access
- 28 March 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (5) , 100544
Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer’s disease
- 28 March 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (5) , 100544
Open AccessPlasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer’s disease
- Open Access
- 23 July 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1422354
Happiness, positive emotions, and subjective well-being in dementia
Research on non-cognitive features of dementia traditionally focusses on neuropsychiatric symptoms and challenging behavior and thus on negative aspects of the disease. Despite the clinical observation that many patients frequently report subjective well-being and often express positive emotions there is only little research on the definition, measurement and determinants of subjective well-being and happiness in people living with dementia. Furthermore, the few studies there are, examined happiness using retrospective questionnaires and the accounts of relatives or caregivers. However, in dementia, the experiencing self becomes more significant since past and future thinking are fading into the background. Here, we review the relative scarce literature in this field, discuss different psychological constructs and their applicability for dementia research, and suggest methods for measuring the addressed constructs in people with dementia. In particular, we propose methodology to study happiness and positive emotions in the experienced moment of the participants using ecological momentary assessments (EMA). We believe that adequate measures of momentary subjective well-being might become an important outcome parameter in clinical dementia trials beyond the currently used quality of life measures.
- 23 July 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1422354
Open AccessHappiness, positive emotions, and subjective well-being in dementia
Research on non-cognitive features of dementia traditionally focusses on neuropsychiatric symptoms and challenging behavior and thus on negative aspects of the disease. Despite the clinical observation that many patients frequently report subjective well-being and often express positive emotions there is only little research on the definition, measurement and determinants of subjective well-being and happiness in people living with dementia. Furthermore, the few studies there are, examined happiness using retrospective questionnaires and the accounts of relatives or caregivers. However, in dementia, the experiencing self becomes more significant since past and future thinking are fading into the background. Here, we review the relative scarce literature in this field, discuss different psychological constructs and their applicability for dementia research, and suggest methods for measuring the addressed constructs in people with dementia. In particular, we propose methodology to study happiness and positive emotions in the experienced moment of the participants using ecological momentary assessments (EMA). We believe that adequate measures of momentary subjective well-being might become an important outcome parameter in clinical dementia trials beyond the currently used quality of life measures.
- 13 October 2021
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 272 (1) , 53-66
The impact of COVID-19-related distress on levels of depression, anxiety and quality of life in psychogeriatric patients
Within the elderly population, psychogeriatric patients may be particularly susceptible to negative mental health effects of the coronavirus crisis. Detailed information about the psychosocial well-being of psychogeriatric patients during the pandemic is still sparse. Here we examined which aspects of subjective experience of the COVID-19 pandemic especially affect levels of depression, anxiety and quality of life in psychogeriatric patients with and without cognitive impairment. A cross-sectional paper survey was conducted during the first German lockdown among patients with a diagnosed psychiatric disorder (≥ 60 years) or a diagnosed neurodegenerative disease (regardless of their age) from the department for neurodegenerative diseases and geriatric psychiatry at the University of Bonn. The WHO-5-, GAD-7- and WHOQOL-old score were used to determine levels of depression, anxiety and quality of life. The second part obtained information about the subjective experience of the COVID-19 pandemic. Statistical analysis included among others principal component analysis and multiple linear regression analysis. COVID-19-related, immediate distress was a strong predictor of elevated symptoms of depression, anxiety and a reduced quality of life. COVID-19-related concerns regarding health and financial security, however, were not significantly associated with negative mental health outcomes. The overall prevalence of symptoms of depression (50.8% [95% CI 43.8–57.6%]) and anxiety (32.7% [95% CI 26.4–39.2%]) among psychogeriatric patients was high. Our findings indicate that psychogeriatric patients are not significantly affected by COVID-19-related concerns but are primarily suffering from emotional consequences resulting from changed living conditions due to the pandemic.
- 13 October 2021
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 272 (1) , 53-66
The impact of COVID-19-related distress on levels of depression, anxiety and quality of life in psychogeriatric patients
Within the elderly population, psychogeriatric patients may be particularly susceptible to negative mental health effects of the coronavirus crisis. Detailed information about the psychosocial well-being of psychogeriatric patients during the pandemic is still sparse. Here we examined which aspects of subjective experience of the COVID-19 pandemic especially affect levels of depression, anxiety and quality of life in psychogeriatric patients with and without cognitive impairment. A cross-sectional paper survey was conducted during the first German lockdown among patients with a diagnosed psychiatric disorder (≥ 60 years) or a diagnosed neurodegenerative disease (regardless of their age) from the department for neurodegenerative diseases and geriatric psychiatry at the University of Bonn. The WHO-5-, GAD-7- and WHOQOL-old score were used to determine levels of depression, anxiety and quality of life. The second part obtained information about the subjective experience of the COVID-19 pandemic. Statistical analysis included among others principal component analysis and multiple linear regression analysis. COVID-19-related, immediate distress was a strong predictor of elevated symptoms of depression, anxiety and a reduced quality of life. COVID-19-related concerns regarding health and financial security, however, were not significantly associated with negative mental health outcomes. The overall prevalence of symptoms of depression (50.8% [95% CI 43.8–57.6%]) and anxiety (32.7% [95% CI 26.4–39.2%]) among psychogeriatric patients was high. Our findings indicate that psychogeriatric patients are not significantly affected by COVID-19-related concerns but are primarily suffering from emotional consequences resulting from changed living conditions due to the pandemic.